Red Jacket: Adele Gulfo, a commercialization guru

With a knack for melding science and patient-focused marketing techniques, the CEO of the biopharma commercial unit at Sumitomo Pharma America has notched blockbuster successes throughout her career.

By Karissa Waddick • Oct. 27, 2023

Patient groups have become a powerhouse in R&D. Here’s a look at their impact.

“They have the money,” and they’re using it to influence drug development, according to the executive director of the IQVIA Institute for Human Data Science.

By Kelly Bilodeau • Oct. 25, 2023

Explore the Trendline➔

Artificial intelligence & machine learning

After years of excited buzz around the potential of artificial intelligence and machine learning, pharma has begun to realize the true implications and potential value of these technologies.

By PharmaVoice staff

Actor and epilepsy advocate Greg Grunberg wants the world to ‘talk about it’

The actor of “Heroes” and “Star Wars: The Force Awakens” fame is starring in another role as a patient advocate for people with epilepsy.

By Michael Gibney • Oct. 19, 2023

From the rainforest to Wall Street — Jaguar Health’s big play for revitalization

A pharma with a massive collection of rainforest-derived plants needs a regulatory win to overcome last year’s financial decline.

By Kelly Bilodeau • Oct. 17, 2023

PharmaVoice 100s: Rare disease warriors

Biopharma leaders pounding away at rare diseases so patients with few other options can have healthier lives.

By Michael Gibney • Oct. 16, 2023

Branded: The trademarks pharma leaders look up to

What do brands like Patagonia, Nike and Lego have to do with pharma? Here are some of the brands industry leaders relate to most — and how they inspire work in the life sciences.

By PharmaVoice Staff • Oct. 13, 2023

PharmaVoice 100s: Patient heroes

Leaders innovating new ways to incorporate patient voices in drug development and decrease barriers to access. 

By Karissa Waddick • Oct. 13, 2023

A decade later, biotech’s CRISPR revolution is still going strong

Once the specialty of a few select drugmakers, CRISPR gene editing is now an essential technology for a growing group of biotechs, many led by former students of the field's pioneering scientists.

By Gwendolyn Wu , Shaun Lucas , Julia Himmel • Oct. 12, 2023

To close the pediatric innovation gap, this biotech has to think differently

Day One Biopharmaceuticals is bucking the cancer drug development trend by working with children and adults simultaneously.

By Alexandra Pecci • Oct. 11, 2023

3 recent FDA adcomm rejections — and why they matter

Decisions that could spell doom for drugs in development and already on the shelves.

By Meagan Parrish • Sept. 29, 2023

Do humans have a place in pharma’s AI future?

From COTA’s large datasets and AI model assistants to a company guiding patients through cancer care, AI can help — but it’s a long way from human-free.

By Michael Gibney • Sept. 26, 2023

Elderly exclusion: Clinical trials still fall short enrolling older adults

Despite high rates of disease in older populations, systemic issues are keeping them out of research studies.

By Kelly Bilodeau • Sept. 25, 2023

Optimizing your hub services program with a gross-to-net lens

In today’s Biopharma landscape, considering Gross-to-Net is essential for effectively designing and optimizing patient support programs.

Sept. 25, 2023

Three years after an FDA rejection, DBV sees a path for its peanut patch

Despite lower-than-expected demand for a competing treatment, DBV’s chief medical officer says the company’s topical skin patch could be a game-changing option for patients.

By Karissa Waddick • Sept. 22, 2023

As the opioid crisis seethes, a long-lasting treatment could offer new ammunition

Launched this month, Brixadi from Braeburn gives patients a new tool to overcome addiction.

By Michael Gibney • Sept. 21, 2023

What happened to ivermectin?

The saga of the anti-parasitic drug continues.

By Alexandra Pecci • Sept. 20, 2023

The 2023 PharmaVoice 100

This year’s honorees are influential and devoted leaders lifting the pillars of the industry to new heights.

By Julia Himmel • Sept. 19, 2023

O.G. Ice-T teams up with Sanofi in horror-themed flu vax ad

The French pharma’s latest vaccine campaign aims to raise awareness about the flu’s complications for marginalized groups. 

By Karissa Waddick • Sept. 14, 2023

Catching up with 2022 PharmaVoice 100 honorees

Tapping into our growing community for expertise and inspiration.

By Meagan Parrish • Sept. 13, 2023

A healthcare paradox: Drugs are too expensive but ‘easy’ to afford, Americans say

A new poll shows that Americans generally support several key IRA provisions, including Medicare price negotiations.

By Alexandra Pecci • Sept. 12, 2023

Roz Brewer announces sudden departure as CEO of Walgreens

The exec who set out to overhaul the long-time pharmacy giant offered few details on why she's stepping down.

By Meagan Parrish • Sept. 1, 2023

A startup’s psychedelic delivery tech is grabbing attention. Will pharma listen?

Psycheceutical is developing a back-of-the-neck topical treatment for ketamine but believes the delivery route holds promise for far more drugs.

By Meagan Parrish • Sept. 1, 2023

Why pharma isn’t done tackling migraines

In the high-growth but competitive field of migraine treatments, CGRP drugs have changed the game — but the search is still on for more options. 

By Kelly Bilodeau • Aug. 28, 2023

Henrietta Lacks’ immortal cells put biopharma profits under a microscope

The HeLa cell line’s contributions to medical science were obtained without permission, and now biotechs profiting from its use are answering for it.

By Michael Gibney • Aug. 23, 2023

A rare disease researcher aims to tackle disability discrimination in new lawsuit

How a pediatric neurologist is advocating for herself and the disabled community in a legal battle with the Howard Hughes Medical Institute.

By Alexandra Pecci • Aug. 22, 2023